Acne Related to Dietary Supplements
When treating patients with acne, obtaining an accurate medication history is recommended to...
Read More
Author: Rebecca Shover
Six States Set Records for COVID-19 Hospitalizations
WEDNESDAY, Oct. 7, 2020 (HealthDay News) — Records for COVID-19 hospitalizations were set...
Read More
A Closer Look at the Association of Alcohol Intake With Hypertension in Type 2 Diabetes
Hypertension is a major global public health concern and continues to be the leading cause of...
Read More
FDA Warns that ’Benadryl Challenge’ Can Have Deadly Side Effects for Teens
Agency responds to reports of severe reactions in participants in viral TikTok trend WASHINGTON...
Read More
Early Introduction of Gluten Linked to Decline in Celiac Disease
WEDNESDAY, Sept. 30, 2020 (HealthDay News) — Introduction of gluten from age 4 months is...
Read More
Bronchitis in Early Childhood Linked to Later Lung Disease
THURSDAY, Oct. 1 2020 (HealthDay News) — Children who have bronchitis at least once before...
Read More
Pancreas development and the Polycomb group protein complexes.
The dual nature of pancreatic tissue permits both endocrine and exocrine functions. Enzymatic...
Read More
Tumor-associated macrophages derived from cancer stem cells.
Macrophages are the most abundant immune cells in the microenvironment of solid tumors. The...
Read More
Strategies for Addressing Influenza Vaccination Hesitancy With Patients
Although many patients are aware of the risks associated with influenza, they may still be...
Read More
Hepatitis B Screening Before Cancer Therapy
“Most patients with hepatitis B virus (HBV) infection do not know that they currently have or have...
Read More
ESMO: Lorlatinib outperforms crizotinib in ALK-positive advanced NSCLC
Lorlatinib is a third generation ALK tyrosine kinase inhibitor. The phase 3 CROWN study shows...
Read More
ESMO: DANUBE does not meet its primary endpoint
Most patients with metastatic urothelial cancer respond to first-line chemotherapy but relapse...
Read More
ESMO: Nivolumab plus chemotherapy: the new standard for first-line treatment of gastric cancer?
Both CheckMate-649 and ATTRACTION-4 showed a statistically significant improvement in...
Read More
ESMO: Bispecific antibodies targeting PD-1 and CTLA-4: new kids on the block(ade)
Several clinical trials have showed that combining an anti-CTLA-4 inhibitor and an anti-PD-(L)1...
Read More
ESMO: PD-L1 density, a new predictive biomarker in NSCLC
PD-L1 expression is commonly used to predict response to immune checkpoint inhibitor therapy....
Read More
ESMO: Abemaciclib improves invasive disease-free survival in high-risk early breast cancer
While many patients with hormone receptor (HR)-positive and human epidermal growth factor receptor...
Read More
ESMO: Adjuvant osimertinib in NSCLC reduces risk of CNS recurrence
Patients with resectable non-small cell lung cancer (NSCLC) often develop (fatal) distant...
Read More
ESMO: Dual AR/AKT blockade effective in mCRPC with PTEN loss
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease. The phase 3...
Read More
ESMO: No advantage of post-operative radiotherapy in patients with stage IIIA N2 NSCLC
The merits of post-operative radiotherapy (PORT) in completely resected non-small cell lung cancer...
Read More
ESMO: CDK4/6 inhibitor palbociclib effective in ER+ advanced endometrial cancer
No standard treatment has been defined yet for second- or third-line systemic treatment of...
Read More